Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig. 1AB
Jourdeuil K et al. (2025)
|
Xla Wt + zmym2
NF13-14 (in situ hybridization)
|
|
|
|
Fig. 3A
Delhermite J et al. (2022)
|
Xla Wt + fbl MO
NF15-18 (in situ hybridization)
|
|
|
|
Fig.4.A
Perfetto M et al. (2021)
|
Xtr Wt + AKTi
NF12.5 (in situ hybridization)
|
|
|
|
Fig.S.2
Perfetto M et al. (2021)
|
Xtr Wt + ddx3x
NF12.5 (in situ hybridization)
|
|
|
|
Fig.1.B-C
Perfetto M et al. (2021)
|
Xtr Wt + ddx3x MO
NF12.5 (in situ hybridization)
|
|
|
|
Fig.5.C
Perfetto M et al. (2021)
|
Xtr Wt + ddx3x MO
NF12.5 (Other Detection Assay)
|
|
|
|
Fig. 4 E, Sup. Fig. 2 B
Neilson KM et al. (2020)
|
Xla Wt + mcrs1
NF13-18 (in situ hybridization)
|
|
|
|
Fig. 2 E O
Neilson KM et al. (2020)
|
Xla Wt + mcrs1 MO
NF13-18 (in situ hybridization)
|
|
|
|
Fig. 2 A
Shah AM et al. (2020)
|
Xla Wt + six1
NF13 (in situ hybridization)
|
|
branchiootorenal syndrome
branchiootic syndrome
|
|
Fig. 2 B
Shah AM et al. (2020)
|
Xla Wt + six1
NF13 (in situ hybridization)
|
|
branchiootorenal syndrome
branchiootic syndrome
|